Skip to main content

Table 2 Assessing risk of bias of the included studies by validated Jadad 5-point scale

From: Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Author Publication year Country Sample size (n) Study Design Randomization (0–2 points) Double-blind (0–2 points) Drop-outs and withdrawals (0–1 points) Jadad score
Sprague [27] 2003 USA 263 multicenter, double-blind, parallel 1 2 1 4
Gafor [26] 2009 Malaysia 25 single-center, open-labelled, parallel 1 0 1 2
Lund [25] 2010 USA 18 single-center, double-blind, crossover 1 2 1 4
Hansen [24] 2011 Denmark 86 multicenter, open-labelled, crossover 2 0 1 3
Ong [23] 2013 Malaysia 66 multicentre, open-labelled, parallel 1 0 1 2
Jamaluddin [22] 2014 Malaysia 26 single-center, open-labelled, parallel 1 0 1 2
Akizawa [21] 2015 Japan 255 multicenter, double-blind, parallel 1 2 1 4
Veceric [28] 2016 Slovenia 20 single-center, open-labelled, parallel 1 0 0 1